Codexis, Inc.

Merck + Co., Inc.

Other

Merck Sharp + Dohme Corp.

Merck Canada Inc.

Jeffrey C Moore

Oscar Alvizo

Jovana Nazor

Jacob M Janey

Derek J Smith

Steven James Collier

Haibin Chen

Scott J Novick

Nicholas John Agard

Vesna Mitchell

Stefanie Ng Minor

Wan Lin Yeo

Joly Sukumaran

Xiyun Zhang

Gregory Hughes

Gjalt W Huisman

Robert Osborne

Gregory Allan Cope

Erika M Milczek

Khin Yu Naing Htwe

Emily Mundorff

Christopher K Savile

Paul N Devine

Melissa Ann Mayo

Nikki Dellas

Da Duan

Agustina Rodriguez-Granillo

Jack S Liang

Jonathan Vroom

Fabien Louis Cabirol

Yong Koy Bong

Yang Hong

Tao Li

Keith Allen Canada

Mark A Huffman

Rama Voladri

Birgit Kosjek

Cathy D Santa Cruz

Jie Yang

Anupam Gohel

Goutami Banerjee

Vinay M Girijavallabhan

John Y L Chung

James Nicholas Riggins

David Entwistle

Zhiguo Jake Song

Ravi David Garcia

Edward Cleator

Nicholas M Marshall

Martina Quintanar-Audelo

Grant S Murphy

Deeptak Verma

Jay Russell

Anupam Gohel Prafulchandra

Shane Grosser

Matthew Truppo

Xiang Yi

Jonathan S Penfield

Iman Farasat

Santhosh Sivaramakrishnan

Auric Anthony Sowell-Kantz

Kevin Matthew Maloney

John Y Chung

Stephen Philip Keen

Andrew William Gibson

Nandhitha Subramanian

Hong Yang

Christophe Mellon

Paul O'Shea

David R Lieberman

Louis-Charles Campeau

Feng Peng

Michael G Sturr

Matthew D Truppo

Kathleen McLaughlin

Jaehon Kim

Jongrock Kong

Danny Gauvreau

Melina Girardin-Rondeau

Stephane Ouellet

Khin Yu Htwe

Paul O'shea

Kevin M Belyk

Mark Mclaughlin

Alejandro Dieguez Vazquez

Michael J Williams

Stephane G Quellet

The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Engineered phosphopentomutase variant enzymes

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Polynucleotides encoding engineered imine reductases

The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

P450-BM3 variants with improved activity

The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Transaminase biocatalysts

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Engineered proline hydroxylase biocatalysts for hydroxylation of chemical compounds

The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.

Ketoreductase polypeptides and polynucleotides

The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Biocatalysts and methods for hydroxylation of chemical compounds

The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Engineered purine nucleoside phosphorylase variant enzymes

Vectors for expression of biocatalysts

Growing community of inventors

Westfield, NJ, United States of America

Jeffrey C Moore